Nutshell Therapeutics is a clinical-stage biotech company specialized in the discovery and development of small-molecule allosteric drugs to tackle historically undruggable targets. We have established a proprietary AI + physics based computational platform named ALLOSTARTM that can identify the potential allosteric pockets on novel proteins, evaluate allosteric effects, and denovo-generate or optimize allosteric ligands. To address the unmet medical needs and fully leverage the advantages of small-molecule allosteric drugs as well as our technical expertise, we have built strong pipelines with potential BIC/FIC allosteric activator or inhibitor molecules in the therapeutic focus of oncology, cardiovascular and metabolic diseases.
